voclosporin + simvastatin

This entry refers to the combination of **voclosporin**, a calcineurin inhibitor immunosuppressant approved for lupus nephritis, and **simvastatin**, a statin (HMG-CoA reductase inhibitor) used primarily to lower cholesterol and prevent cardiovascular disease. There is no approved fixed-dose preparation combining voclosporin and simvastatin; this describes potential co-administration. Voclosporin inhibits calcineurin, reducing T cell activation and suppressing immune response, while simvastatin inhibits HMG-CoA reductase, lowering cholesterol synthesis in the liver.[1][2][3][4] The combination is of particular interest because voclosporin is known to interact with statins by inhibiting certain hepatic transporters (OATP1B1/OATP1B3), increasing exposure to simvastatin acid, and possibly increasing the risk of statin-induced adverse effects such as myopathy and rhabdomyolysis; patients should be monitored.[1]